Researchers Studying Oral Medicine to Treat Newly Diagnosed High-Grade Glioma With NTRK Fusion
Phase: Recruiting
First Posted: January
Condition(s): High-Grade Glioma With NTRK Fusion
NCT Number: NCT04655404 Other Study ID Number(s): CONNECT1903
What Is the Purpose of This Study?
To learn more about the effects of a study drug on children with brain tumors. We want to learn how well it works to shrink brain tumors when used alone or when given with standard chemotherapy or after radiation therapy.
Who Can Take Part in This Study?
People who may be eligible for this study:
- Are newly diagnosed high-grade (HGG), including diffuse intrinsic pontine gliomas (DIPG).
- Are birth to 21 years old.
For a full list of eligibility requirements, visit https://clinicaltrials.gov/study/NCT04655404
What Will Happen During This Study?
- Patients will take oral medicine for two cycles or take part in a surgical portion of the study.
Principal Investigator
Discover More Research
Explore additional studies relating to neuro-oncologyYour Might Also Be Interested In
Neuro-Oncology
Our highly experienced and internationally recognized team of pediatric neuro-oncologists, neurosurgeons and neuroradiologists will care for your child by providing the most advanced and innovative treatments, while at the same time, paying careful attention to all the needs and concerns of your child and family.
High-Grade Gliomas
High-grade gliomas are fast-growing cancers that form in the brain or spinal cord. Surgery, radiation, and targeted therapies can help. High-grade gliomas are more aggressive and can grow quickly. They are the second most common type of malignant brain tumor in children.
Brain Tumors
Brain tumors are the most common solid tumors in children. Primary brain tumors start in the brain and usually do not spread outside the brain tissue.